• 1
    Stock PG, Roland ME, Carlson L et al. Kidney and liver transplantation in human immunodeficiency virus-infected patients: a pilot safety and efficacy study. Transplantation 2003; 76: 370375.
  • 2
    Roland ME. Solid-organ transplantation in HIV-infected patients in the potent antiretroviral therapy era. Top HIV Med 2004; 12: 7376.
  • 3
    Ragni MV, Belle SH, Im K et al. Survival of human immunodeficiency virus-infected liver transplant recipients. J Infect Dis 2003; 188: 14121420.
  • 4
    Roland ME, Stock PG. Review of solid-organ transplantation in HIV-infected patients. Transplantation 2003; 75: 425429.
  • 5
    Stock P, Roland M, Carlson L et al. Solid organ transplantation in HIV-positive patients. Transplant Proc 2001; 33: 36463648.
  • 6
    Brennan DC, Flavin K, Lowell JA et al. Leukocyte response to thymoglobulin or atgam for induction immunosuppression in a randomized, double-blind clinical trial in renal transplant recipients. Transplant Proc 1999; 31(3B Suppl): 16S18S.
  • 7
    Muller TF, Grebe SO, Neumann MC et al. Persistent long-term changes in lymphocyte subsets induced by polyclonal antibodies. Transplantation 1997; 64: 14321437.
  • 8
    Muller TF, Grebe SO, Reckzeh B, Borutta A, Radsak K, Lange H. Short- and long-term effects of polyclonal antibodies. Transplant Proc 1999; 31(3B Suppl): 12S15S.
  • 9
    Muller T, Sprenger H, Keuchel M et al. Diagnosis of viral infections under therapy with OKT3 and antithymocyte globulin. Transplant Proc 1992; 24: 26362638.
  • 10
    Buchler M, Hurault de Ligny B, Madec C, Lebranchu Y. Induction therapy by anti-thymocyte globulin (rabbit) in renal transplantation: a 1-yr follow-up of safety and efficacy. Clin Transplant 2003; 17: 539545.
  • 11
    Rubin RH, Cosimi AB, Hirsch MS, Herrin JT, Russell PS, Tolkoff-Rubin NE. Effects of antithymocyte globulin on cytomegalovirus infection in renal transplant recipients. Transplantation 1981; 31: 143145.
  • 12
    Benson CAKJ, Masur H, Pau A, Holmes KK. Treating opportunistic infections among HIV-infected adults and adolescents. MMWR Recomm Rep 2004; 53: 1112.
  • 13
    Colvin RB, Cohen AH, Saiontz C et al. Evaluation of pathologic criteria for acute renal allograft rejection: reproducibility, sensitivity, and clinical correlation. J Am Soc Nephrol 1997; 8: 19301941.
  • 14
    Boyd AS. Organ transplantation in HIV-positive patients. N Engl J Med 1990; 323: 1492.
  • 15
    Swanson SJ, Kirk AD, Ko CW, Jones CA, Agodoa LY, Abbott KC. Impact of HIV seropositivity on graft and patient survival after cadaveric renal transplantation in the United States in the pre highly active antiretroviral therapy (HAART) era: an historical cohort analysis of the United States Renal Data System. Transpl Infect Dis 2002; 4: 144147.
  • 16
    Spital A. Should all human immunodeficiency virus-infected patients with end-stage renal disease be excluded from transplantation? The views of U.S. transplant centers. Transplantation 1998; 65: 11871191.
  • 17
    USRDS 2004 annual data report. Am J Kidney Dis 2005; 45: 8280.
  • 18
    Kimmel PL. The nephropathies of HIV infection: pathogenesis and treatment. Curr Opin Nephrol Hypertens 2000; 9: 117122.
  • 19
    Palella FJ, Jr., Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853860.
  • 20
    Mocroft A, Katlama C, Johnson AM et al. AIDS across Europe, 1994–98: the EuroSIDA study. Lancet 2000; 356: 291296.
  • 21
    Kaplan JE, Hanson D, Dworkin MS et al. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis 2000; 30(Suppl 1): S5S14.
  • 22
    Detels R, Tarwater P, Phair JP, Margolick J, Riddler SA, Munoz A. Effectiveness of potent antiretroviral therapies on the incidence of opportunistic infections before and after AIDS diagnosis. Aids 2001; 15: 347355.
  • 23
    Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Recommendations of the panel on clinical practices for treatment of HIV. MMWR Recomm Rep 2002; 51: 155.
  • 24
    Bica I, McGovern B, Dhar R et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 32: 492497.